Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non ‐small cell lung cancer: Chinese multicenter report and literature review

ConclusionsThese data indicate that ICI consolidation therapy can achieve favorable short ‐term efficacy, while exhibiting good safety and acceptable toxicity profiles in Chinese patients with unresectable stage III NSCLC.Key pointsSignificant findings of the studyThis is the first report evaluating the safety and efficacy of ICI consolidation therapy after chemoradiotherapy in China. Our results indicate that ICI consolidation is associated with favorable efficacy and no severe pneumonitis incidence in Chinese patients undergoing both anti ‐PD‐1 and anti‐PD‐L1 monoclonal antibody consolidation.What this study addsPost ‐hoc analysis of the Japanese subgroup in the PACIFIC study suggested that consolidation therapy may be associated with increased pneumonitis incidence in Asian patients. However, our findings indicate that consolidation therapy is safe and tolerable in Chinese patients with unresectable stage III NSCLC.

Source: Thoracic Cancer - August 23, 2020 Category: Cancer & Oncology Authors: Tao Zhang, Kunpeng Xu, Nan Bi, Li Zhang, Wei Jiang, Jun Liang, Lei Deng, Xin Wang, Jianyang Wang, Jie Wang, Luhua Wang Tags: ORIGINAL ARTICLE Source Type: research